LEO Pharma's Chronic Hand Eczema Study Makes Headlines In The Lancet

LEO Pharma A/S, a global frontrunner in medical dermatology, has announced that The Lancet, one of the world’s most prestigious peer-reviewed journals, has published the results from the DELTA 1 and DELTA 2 phase 3 clinical trials of delgocitinib cream. This marks the first time The Lancet has featured data on a new topical pan-Janus kinase (JAK) inhibitor aimed at treating moderate to severe chronic hand eczema (CHE).

The publication details the randomized, double-blinded, multi-center vehicle-controlled trials, which assessed the safety and efficacy of delgocitinib cream compared to a placebo vehicle. The trials focused on adult patients with moderate to severe CHE who had not responded adequately to other treatments or for whom topical corticosteroids were not suitable. Delgocitinib cream is still under investigation and has not yet received approval from any regulatory authority.

Kreesten Meldgaard Madsen, Chief Development Officer, Leo Pharma, said in a statement, “Having the DELTA 1 and 2 trial results featured in one of the most highly regarded peer-reviewed medical journals in the world is a vital step on our mission to raise awareness and develop potential new treatment options for those living with CHE. The publication of our research in The Lancet is a proud milestone for everyone who has worked tirelessly on the DELTA 1 and 2 trials, and proves LEO Pharma’s commitment to pioneering new potential treatment options for those living with skin conditions. We are excited to share this analysis with the broader scientific and medical community to help drive further research advances for CHE.”

Dr. Robert Bissonnette, Lead Author and MD from Innovaderm Research, Montreal, commented, “Historically, CHE has been under researched, so the publication of the DELTA 1 and 2 trials in The Lancet is a positive step towards highlighting the condition, and in turn indicates the increased quality and rate of research in the space. Publication of milestones like this have a valuable role in our efforts to improve the day-to-day reality of those living with CHE.”